Using very low doses of GLP-1 receptor agonists (medications typically intended for metabolic conditions) could provide health benefits, such as a reduction in inflammation or the control of addictions, independently of weight loss.

noli's read

The community is divided: while some view these molecules as a lever for optimization, others warn of the real risk of muscle loss (sarcopenia), a pillar of long-term vitality. Scientifically, the anti-inflammatory and neurological benefits of GLP-1 are documented in preclinical studies and observational analyses (Source: Nature Medicine), but their off-label use in lean individuals remains speculative. It is proven that these substances reduce appetite, which, in a person without excess weight, can lead to involuntary protein malnutrition and therefore to a loss of muscle mass that is difficult to compensate for (Source: RCTs on weight maintenance, New England Journal of Medicine). The idea that these benefits can be dissociated from weight loss remains a hypothesis: it is complex to distinguish the direct effects of the molecule from those linked to changes in dietary habits. Finally, the use of these molecules for 'longevity' without metabolic pathology lacks robust clinical evidence and involves documented risks, particularly digestive and metabolic. The community consensus is mixed, oscillating between enthusiastic curiosity and clinical caution regarding potential side effects.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022
5. 5r/PeterAttia